Journal of Liver Cancer

Review Articles

Multidisciplinary approaches to downstaging hepatocellular carcinoma: present and future: Sang-Youn Hwang, Hyunwook Choi, Wan Jeon, Ryoung-Go Kim; J Liver Cancer. 2024;24(2):171-177. Published online September 5, 2024; DOI: https://doi.org/10.17998/jlc.2024.08.30

11,861 Views
386 Downloads
6 Web of Science
8 Citations

Downstaging of hepatocellular carcinoma (HCC) is typically defined as the reduction in size or number of viable tumors through locoregional therapy (LRT), aiming to meet the established criteria for liver transplantation (LT). According to the Barcelona Clinic Liver Cancer (BCLC) staging system, a subgroup of patients with BCLC-B may benefit most from downstaging therapies. The United Network Organ Sharing downstaging protocol identifies potential candidates for downstaging by setting out ‘inclusion criteria’ and defining ‘successful downstaging.’ Additionally, the protocol considers factors related to tumor biology, such as an alphafetoprotein level <500 ng/mL after LRT. Reports indicate that successful downstaging rates following LRT are about 50%, with post- LT recurrence rates comparable to those of patients within the Milan criteria. A comprehensive multicenter US study on 10-year outcomes post-LT after downstaging showed 10-year post-LT survival and recurrence rates of 52.1% and 20.6%, respectively, for patients whose disease was downstaged; this compares to 61.5% and 13.3% for those consistently within the Milan criteria. Recently, the development of effective systemic treatments for HCC, such as immuno-oncologic agents, has provided additional opportunities for downstaging. Numerous clinical trials are exploring a multidisciplinary approach (MDA) combining LRT and systemic therapy. Although concrete evidence of the superiority of MDA for HCC downstaging is lacking, some retrospective studies and phase I and II trials have shown promising results regarding the efficacy and safety of MDA for this purpose. In this review, we will also discuss the future of MDA protocols in downstaging for improved clinical outcomes.

Citations

Citations to this article as recorded by

Effectiveness of Downstaging Advanced Hepatocellular Carcinoma for Liver Transplantation: Insights from a Decade of Single-Center Experience
Erin M. Duggan, Nishtha Singh, Joanna K. Weeks, Adam Talenfeld, Benjamin May, Resmi Charalel, Ian Dinmore, Sarah Stucky, Tea Binder, Alexander J. Berman, Yana Glemaud, Arush Anand, Anthony Choi, Rebecca Craig-Schapiro, Dustin Carpenter, Benjamin Samstein,
Digestive Disease Interventions.2026;[Epub] CrossRef
Transarterial Chemoembolization and Immunotherapy: Another Good Marriage?
Landon L. Chan, Stephen L. Chan
Journal of Clinical Oncology.2026; 44(11): 949. CrossRef
Low Tumor Burden Predicts Benefit from Transarterial Treatment in Hepatocellular Carcinoma with Extrahepatic Metastasis: A Nationwide Cohort Study
Jaejun Lee, Hyun Yang, Keungmo Yang, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Si Hyun Bae
Liver Cancer.2026; : 1. CrossRef
Expanding the path to cure - a narrative review on optimizing multimodality sequencing in HCC
Howard J. Lim, Arndt Vogel, Emma M. Dunne, Mayur Brahmania, Vincent C. Tam, Robert J. Abraham, Jennifer J. Knox, Jason K. Wong, Prosanto Chaudhury, Ravi Ramjeesingh, Peter T.W. Kim, Ilidio Martins, Leandro C. Leite, David Valenti, Gonzalo Sapisochin, Davi
Cancer Treatment Reviews.2026; 149: 103194. CrossRef
A concise review of updated global guidelines for the management of hepatocellular carcinoma: 2017-2024
Hyunjae Shin, Su Jong Yu
Journal of Liver Cancer.2025; 25(1): 19. CrossRef
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
Stephen Lam Chan, Hui-Chuan Sun, Yang Xu, Hongmei Zeng, Hashem B El-Serag, Jeong Min Lee, Myron E Schwartz, Richard S Finn, Jinsil Seong, Xin Wei Wang, Valérie Paradis, Ghassan K Abou-Alfa, Lorenza Rimassa, Jia-Horng Kao, Bo-Heng Zhang, Josep M Llovet, Jo
The Lancet.2025; 406(10504): 731. CrossRef
Liver Transplantation for Hepatocellular Carcinoma: A Comprehensive Review
Seok-Hwan Kim
Convergence Hepatology.2025; 1(1): 24. CrossRef
Radioembolization of primary liver tumors for patients with pre-existing ascites: beyond Child-Pugh score
Fayez J. Jabboure, Joshua A. Marlow, Wyatt D. Reed, Naganathan B. Mani, Nassir Rostambeigi
Abdominal Radiology.2025; 51(7): 3418. CrossRef

Multidisciplinary approach for hepatocellular carcinoma patients: current evidence and future perspectives: Joo Hyun Oh, Dong Hyun Sinn; J Liver Cancer. 2024;24(1):47-56. Published online March 25, 2024; DOI: https://doi.org/10.17998/jlc.2024.02.27

13,630 Views
366 Downloads
28 Web of Science
30 Citations

Abstract PDF

Management of hepatocellular carcinoma (HCC) is challenging due to the complex relationship between underlying liver disease, tumor burden, and liver function. HCC is also notorious for its high recurrence rate even after curative treatment for early-stage tumor. Liver transplantation can substantially alter patient prognosis, but donor availability varies by each patient which further complicates treatment decision. Recent advancements in HCC treatments have introduced numerous potentially efficacious treatment modalities. However, high level evidence comparing the risks and benefits of these options is limited. In this complex situation, multidisciplinary approach or multidisciplinary team care has been suggested as a valuable strategy to help cope with escalating complexity in HCC management. Multidisciplinary approach involves collaboration among medical and health care professionals from various academic disciplines to provide comprehensive care. Although evidence suggests that multidisciplinary care can enhance outcomes of HCC patients, robust data from randomized controlled trials are currently lacking. Moreover, the implementation of a multidisciplinary approach necessitates increased medical resources compared to conventional cancer care. This review summarizes the current evidence on the role of multidisciplinary approach in HCC management and explores potential future directions.

Citations

Citations to this article as recorded by

Therapeutic Strategies for Hepatocellular Carcinoma: Current Advances and Future Perspectives
Palaniyandi Muthukutty, Jeong Heo, So Young Yoo
Vaccines.2026; 14(2): 189. CrossRef
The Role of the Multidisciplinary Team in the Management of Complex Cases of Liver Disease in a Peripheral Hospital: A Retrospective Analysis of MDT Registry
Gabriele A. Vassallo, Tommaso Dionisi, Angelo Randazzo, Antonio Limblici, Monica Failla, Marcella Ferraro, Oriana Maiorana, Eleonora Taibi, Filomena Pietrantonio, Francesca Brovelli, Giovanni Addolorato, Giuseppe Augello
Health Science Reports.2026;[Epub] CrossRef
Using period analysis to timely provide serial data on long-term survival for liver cancer patients from China
Pengtao Chen, Wei Gu, Xin Bing, Liangyou Wang, Yongran Cheng, Xukai Chen, Dinghu Zhang, Tianhui Chen
Frontiers in Oncology.2026;[Epub] CrossRef
Hepatocellular carcinoma: current aspects of multidisciplinary management. Part 2. Treatment and prevention
Yu.M. Stepanov, N.Yu. Zavhorodnia, O.M. Vlasova
GASTROENTEROLOGY.2026; 60(1): 52. CrossRef
Multidisciplinary Clinic Approach Improves Immunotherapy Treatment Outcomes in Unresectable Hepatocellular Carcinoma: A Multicentre Retrospective Study
Andrea Dalbeni, Alessandra Auriemma, Marco Vicardi, Filippo Cattazzo, Maria Elena Bellucco, Chiara Mazzarelli, Federica Villa, Giulia Dispinzieri, Leonardo Antonio Natola, Caterina Soldà, Sara Lonardi, Luisa Foltran, Sara Torresan, Simone Rota, Tiziana Pr
Liver Cancer.2026; : 1. CrossRef
Prognostic significance of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in hepatocellular carcinoma: a retrospective multicenter study on overall and recurrence-free survival following liver resection or liver transplantation
Konstantinos Arvanitakis, Spyridon Pantzios, Chrysanthos Christou, Vasileios Papadopoulos, Eleni Theocharidou, Christos Topalidis, Georgios Kalopitas, Orestis Sidiropoulos, Antonios Chatzigeorgiou, Ioannis Mitroulis, Triantafyllia Koletsa, Prodromos Hytir
Frontiers in Immunology.2026;[Epub] CrossRef
Integrating Network Pharmacology and Clinical Observation to Elucidate the Therapeutic Mechanisms of Yangzheng Xiaoji Decoction in Primary Liver Cancer
Shengbo Yang, Rui Liu, Shuai Wen, Ya Wang, Nan Tai, Jie Tian
International Journal of General Medicine.2026; Volume 19: 1. CrossRef
Pharmaceutical Compounding as a Pillar of Personalized Oncology: Current Applications, Emerging Technologies, and Future Perspectives
Filipa Mascarenhas-Melo, Rafael Pinheiro, Francis Victor, Maria Eugénia Pina, Ana Figueiras
Pharmaceuticals.2026; 19(7): 1077. CrossRef
Comparative Analysis of Albumin-Bilirubin (ALBI) Score and Child-Pugh Score for Prognostic Stratification in Hepatocellular Carcinoma Patients: A Single-Center Experience From North India
Varun Goel, Arpit Jain, Nivedita Patnaik, Dharmishtha A Basu, Prateek Gupta, Shaifali Goel, Pankaj Goel, Vineet Talwar, Shivendra Singh
Cureus.2026;[Epub] CrossRef
Teaching design for chapter “primary liver cancer” in surgery course based on the clinical theory and clerkship synchronization model in the era of New Medicine
Feng Ye, Qiang Cai, Xiaoyong Gong, Jiajun Ren, Ruixin Sun, Chang Liu, Xiaoli Wang, Yuan Qiao
Global Medical Education.2025; 2(1): 149. CrossRef
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang
Clinical and Molecular Hepatology.2025; 31(Suppl): S228. CrossRef
Roadmap for HCC Surveillance and Management in the Asia Pacific
Masatoshi Kudo, Bui Thi Oanh, Chien-Jen Chen, Do Thi Ngat, Jacob George, Do Young Kim, Luckxawan Pimsawadi, Pisit Tangkijvanich, Raoh-Fang Pwu, Rosmawati Mohamed, Sakarn Bunnag, Sheng-Nan Lu, Sirintip Kudtiyakarn, Tatsuya Kanto, Teerha Piratvisuth, Chao-C
Cancers.2025; 17(12): 1928. CrossRef
Assessment prior to liver tumor resection: what a radiologist needs to know
Mahmoud Diab, Mindy X. Wang, Aarya Ramprasad, Ann A. Shi, Imran Ahmed, Sergio Klimkowski, Vincenzo K. Wong, Khaled M. Elsayes
Abdominal Radiology.2025; 51(3): 1261. CrossRef
Multidisciplinary Team Management of Hepatocellular Carcinoma in the MENA Region: Current Practices, Challenges, and Gaps
Mohamed El-Kassas, Rofida Khalifa, Khalid AlNaamani, Hend Shousha, Yusuf Yilmaz, Faisal Sanai, Maen Almattooq, Asma Labidi, Maisam Akroush, Nabil Debzi, Mohamed Abdelmalek, Nermeen Abdeen, Ali Tumi, Mohamed Elbadry, Amr El Fouly, Eman Marwan, Jassim Al Su
Journal of Hepatocellular Carcinoma.2025; Volume 12: 1315. CrossRef
Advancing explainable AI in healthcare: Necessity, progress, and future directions
Rashmita Kumari Mohapatra, Lochan Jolly, Sarada Prasad Dakua
Computational Biology and Chemistry.2025; 119: 108599. CrossRef
Primary small cell-like hepatocellular carcinoma arising in a patient with fatty liver disease without cirrhosis: a case report and literature review
Hyun Bin Choi, Jeong-Ju Yoo, Susie Chin, Sang Gyune Kim, Young-Seok Kim
Gastroenterology Report.2025;[Epub] CrossRef
Advancements in nanoultrasonics technology for the diagnosis and treatment of liver cancer: discussion on medical ethics and hospital management issues
Weiping Wan, Fan Yang, Yenan Zhang, Jie Wang, Xin Xie, Fangming Guo, Li Han
Nanomedicine.2025; 20(21): 2627. CrossRef
Impact of the 2024 medical-policy conflict on hepatocellular carcinoma management in Korea
Soon Sun Kim, Hyun Yang, Jieun Kwon, Eunju Kim, Jeong Il Yu, Janghan Jung, Woosun Choi, Ji Eun Han, Moon Haeng Hur, Bo Hyun Kim, Sung Hyun Kim, Jeong Han Kim, Haeryoung Kim, Pyoung-Jae Park, Hyun Phil Shin, Su Jong Yu, Ki Tae Yoon, Sang Min Yoon, Minjong
Journal of Liver Cancer.2025; 25(2): 169. CrossRef
Effectiveness of Nursing Care Intervention Among Patients With Hepatocellular Carcinoma Undergoing Surgery: A Systematic Review and Meta‐Analysis
Wei Geng, Danling Wang, Xinwei Feng
International Journal of Nursing Practice.2025;[Epub] CrossRef
Current status and future perspectives of minimally invasive liver surgery for hepatocellular carcinoma
Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Boram Lee, Yeshong Park, Hyelim Joo, Seung Yeon Lim
Journal of Liver Cancer.2025; 25(2): 233. CrossRef
First-in-India experience with 90Y-BhabhaSphere: an indigenous 90Y-TheraSphere biosimilar for transarterial radioembolization of hepatic malignancies
Ashish Kumar Jha, Ameya D Puranik, Kunal Bharat Gala, K V Vimalnath Nair, Ardhi Rajeswari, Sharad P Lohar, Aaditya Shah, Amala M Mathai, Bikash K Tiwary, Nitin Sudhakar Shettye, Anupam Mathur, Usha Pandey, Sudipta Chakraborty, Nilendu Purandare, Suyash Ku
British Journal of Radiology.2025; 98(1176): 2135. CrossRef
CTRP6 in Cancer: Mechanistic Insights and Therapeutic Potential
Muhammad Zubair Mehboob, Xia Lei
Cancers.2025; 17(21): 3409. CrossRef
Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma
Shuichiro Shiina, Ryosuke Tateishi, Joon Il Choi, So Yeon Kim, Zhiqiang Meng, Lujun Shen, Sheng-Nan Lu, Jen-I. Hwang, Maki Tobari, Hitoshi Maruyama, Terguunbileg Batsaikhan, Qing Deng, Lariza Marie Canseco, Yoshinari Asaoka, Shi-Ming Lin, Kai-Wen Huang, H
Liver Cancer.2025; 14(5): 651. CrossRef
Applying quality indicators and multidisciplinary team care to improve long-term survival in early-stage hepatocellular carcinoma
Hui-Ling Huang, Kuan-Chen Pan, Te-Sheng Chang, Shu-Chen Chen, Hsing-Ju Lu, Sheng-Nan Lu
Asia-Pacific Journal of Oncology Nursing.2025; 12: 100804. CrossRef
Overview of the multidisciplinary team activity in patients with hepatocellular carcinoma and their survival outcomes
V. Guarini, C. Garzòn, D. Casado, M. Casanova, P. Villarejo, I. Azinovic, E. Crespo, I. Fernandez, M. Lopez, M.M. de Bourio, M. Moran, M. Jimenez, G. Medrano, V. Castellano, A. Lamarca
ESMO Gastrointestinal Oncology.2025; 10: 100263. CrossRef
Unusual bilateral lymphadenopathy revealing Hodgkin’s lymphoma: a case report
Vaishnavi D. Rajurkar, Keshao Hiwale, Sahitya Vodithala, Nisha D. Barole, Prajakta Nimbalkar
Discover Oncology.2025;[Epub] CrossRef
Exploring the role of liver resection as a first-line treatment option for multinodular BCLC-A hepatocellular carcinoma
Joo Hyun Oh, Dong Hyun Sinn
Journal of Liver Cancer.2024; 24(2): 126. CrossRef
Comparative Effectiveness of Endoscopic Versus Pharmacological Interventions for Variceal Rebleeding in Cirrhosis: A Systematic Review
Muath M Dabas, Muhammad Maqbool, Adees W Bedros, Hiba Mazhar, Papuna Papuashvili, Muhammad Umar, Aqsa B Bajwa, Dhruvi H Patel, Nada B Abushalha, Abid Khattak, Junaid Ahmed, Asma Mehdi
Cureus.2024;[Epub] CrossRef
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
George Lau, Shuntaro Obi, Jian Zhou, Ryosuke Tateishi, Shukui Qin, Haitao Zhao, Motoyuki Otsuka, Sadahisa Ogasawara, Jacob George, Pierce K. H. Chow, Jianqiang Cai, Shuichiro Shiina, Naoya Kato, Osamu Yokosuka, Kyoko Oura, Thomas Yau, Stephen L. Chan, Min
Hepatology International.2024; 18(6): 1661. CrossRef
Modern Management of Common Bile Duct Stones: Breakthroughs, Challenges, and Future Perspectives
Yanguang Sha, Zhilin Wang, Rongmei Tang, Ke Wang, Chen Xu, Guangbin Chen
Cureus.2024;[Epub] CrossRef

Case Reports

Multidisciplinary approach for hepatocellular carcinoma arising from cirrhotic liver with Budd-Chiari syndrome: a case report: Sangmi Kim, Ji Hoon Kim, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung; J Liver Cancer. 2022;22(2):202-206. Published online September 20, 2022; DOI: https://doi.org/10.17998/jlc.2022.09.17

5,722 Views
75 Downloads
1 Citation

Abstract PDF

Budd-Chiari syndrome (BCS) is defined by the obstruction of the hepatic venous outflow between the small hepatic veins and the junction of the inferior vena cava (IVC) with the right atrium. BCS with IVC obstruction occasionally progresses to hepatocellular carcinoma (HCC). Here, we report the case of a patient with HCC arising from a cirrhotic liver with BCS, in whom the hepatic portion of the IVC was obstructed, and who had a favorable outcome with a multidisciplinary approach and IVC balloon angioplasty.

Citations

Citations to this article as recorded by

Multidisciplinary collaboration successfully treated Budd Chiari syndrome complicated with hepatocellular carcinoma rupture and bleeding: A case report
Lian Liao, Yuyang Qiu, Xiaobo Gong
Medicine.2025; 104(51): e46748. CrossRef

Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma: Ahlim Lee, Jaejun Lee, Hyun Yang, Soo-Yoon Sung, Chang Ho Jeon, Su Ho Kim, Moon Hyung Choi, Young Joon Lee, Ho Jong Chun, Si Hyun Bae; J Liver Cancer. 2022;22(1):75-83. Published online March 18, 2022; DOI: https://doi.org/10.17998/jlc.2022.03.04

8,439 Views
114 Downloads
7 Citations

Abstract PDF

Hepatocellular carcinoma (HCC) is a cytotoxic chemotherapy-resistant tumor and most HCCs arise in a background of liver cirrhosis of various causes. Although the IMBrave150 trial showed remarkable advancements in the treatment of unresectable HCC with atezolizumab plus bevacizumab (AteBeva), therapeutic outcomes were unsatisfactory in more than half of the patients. Accordingly, many ongoing trials combine conventional modalities with new drugs such as immune checkpoint inhibitors for better treatment outcomes, and they are expected to benefit patients with limited responses to conventional treatment. Here, two patients with advanced stage HCC with preserved liver function and good performance status showed partial response after treatment with combination or sequential therapy of AteBeva, hepatic arterial infusion chemotherapy, radiation therapy, and transarterial chemoembolization. These findings indicate the efficacy of multidisciplinary treatment against advanced HCC. Additional studies are required to establish optimal treatment strategies.

Citations

Citations to this article as recorded by

Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma
Thaweesak Chieochansin, Kornkan Choomee, Napat Angkathunyakul, Ananya Pongpaibul, Prawat Kositamongkol, Prawej Mahawithitwong, Chutwichai Tovikkai, Wethit Dumronggittigule, Pholasith Sangserestid, Charnwit Assawasirisin, Yongyut Sirivatanauksorn, Mutita J
Biomedicine & Pharmacotherapy.2026; 201: 119731. CrossRef
Multidisciplinary treatment strategies for the assessment of immune, coagulation, and biomarker responses after transarterial chemoembolization for hepatocellular carcinoma
Tian Song, Kan-Hua Wu, Hao Yang, Wen-Li Xie, Lan Shen
World Journal of Gastrointestinal Surgery.2025;[Epub] CrossRef
Navigating the Therapeutic Pathway and Optimal First-Line Systemic Therapy for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
Hyun Phil Shin, Moonhyung Lee
Medicina.2025; 61(12): 2164. CrossRef
Complications of immunotherapy in advanced hepatocellular carcinoma
Young-Gi Song, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
Journal of Liver Cancer.2024; 24(1): 9. CrossRef
Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study
Jae-Sung Yoo, Ji Hoon Kim, Hee Sun Cho, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Suho Kim, Jung Suk Oh, Ho Jong Chun, Pil Soo Sung
Abdominal Radiology.2024; 49(9): 3127. CrossRef
Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Tae Hyun Kim, Bo Hyun Kim, Yu Ri Cho, Young-Hwan Koh, Joong-Won Park
Journal of Liver Cancer.2023; 23(2): 330. CrossRef
Is multidisciplinary treatment effective for hepatocellular carcinoma with portal vein tumor thrombus?
Won Hyeok Choe
Journal of Liver Cancer.2022; 22(1): 1. CrossRef

A Case of Complete Response by Multidisciplinary Management in a Patient with Solitary Bone Metastasis after Curative Resection of Hepatocellular Carcinoma: Seawon Hwang, Hyun Yang, Hae Lim Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon; J Liver Cancer. 2016;16(1):52-56. Published online March 31, 2016; DOI: https://doi.org/10.17998/jlc.16.1.52

2,078 Views
16 Downloads

Abstract PDF: Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the prognosis of patients with extrahepatic metastasis from HCC still remains dismal. The current study presents a case of HCC that was metastatic to the pelvis and describes successful treatment with multidisciplinary approach to the skeletal metastasis. The patient was a 67-year-old male who presented with right pelvic pain 28 months following right hepatectomy for HCC. Computed tomography and magnetic resonance imaging indicated a solitary bone metastasis without intrahepatic recurrence. Complete response was achieved with multidisciplinary management including sorafenib, transarterial embolization, surgery to remove the metastatic mass and radiotherapy after surgery. A post-operative follow-up 15 months later found that the patient remained in good health with maintained complete response. This case suggests that a multidisciplinary approach can achieve long-term cancer-free survival and prolonged life expectancy beyond palliative care for patients with solitary bone metastasis after curative surgery for HCC.

Review Article

Directions for Future Hepatocellular Carcinoma Treatment Guidelines; Hepatologist’s Perspective: Systemic Approach to Multidisciplinary Treatment: Soo Young Park, Won Young Tak; Journal of the Korean Liver Cancer Study Group. 2013;13(1):8-13. Published online February 28, 2013; DOI: https://doi.org/10.17998/jlc.13.1.8

1,977 Views
7 Downloads

Abstract PDF: Hepatocellular carcinoma is one of the most important malignancies in Korea with high mortality rates. Although current guidelines define treatment algorithm by performance status, underlying liver function, size and number of hepatocellular carcinoma, those are not fully reflect the complexities of patients’ characteristics and recently advanced available therapeutic options. Treatment can be optimized by available therapeutic options based on the patients’ characteristics. Because of the heterogeneity in presentation among patients, it is now widely accepted that management of hepatocellular carcinoma requires multimodality and multidisciplinary treatment approaches involving hepatologists, surgeons, interventional radiologists, and radiation oncologists. These approaches are important in improving the survival of patients with hepatocellular carcinoma.

Case Report

A Case of Advanced Hepatocellular Carcinoma Treated with Curative Surgical Resection after Downstaging by Hepatic Arterial Infusion Chemotherapy: Jong Ryul Eun, Heon Ju Lee, Jae Woon Kim, Jay Chun Chang, Sung Su Yun, Joon Hyuk Choi; Journal of the Korean Liver Cancer Study Group. 2011;11(1):60-64. Published online February 28, 2011

1,240 Views
2 Downloads

Abstract PDF: Cure by single modality for advanced hepatocellular carcinoma (HCC) is difficult. Therefore, multidisciplinary approaches are needed to get a better outcome for advanced HCC. In this paper, we report a case of advanced HCC treated with curative surgical resection after downstaging by hepatic arterial infusion chemotherapy (HAIC). A 50-year-old male patient had a maximum 16.0 cm sized HCC in the right lobe. He achieved a partial response after 2 cycles of HAIC with 5-FU (750 mg/m2) and cisplatin (25 mg/m2). After completion of 6 cycles, he received a curative right hepatectomy and the histopathology revealed 95% of tumor necrosis. He is under follow-up without recurrence at 14 months of surgery. This case suggests that surgery after downstaging by HAIC may provide good clinical outcome in advanced HCC.

First
Prev
Page of 1
Next
Last

Search